ALKS catalyst calendar

Alkermes plc.

Upcoming catalysts
8
Cash runway
9.3 months
Cash & investments
$512M
Phase 3 programs
18

Alkermes plc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia on November 15, 2026. There are 8 upcoming events on record.

Cash runway is approximately 9.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 73 concluded trials, 93% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 15, 2026 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia Trial Milestone Phase 2
December 13, 2026 est. Next quarterly earnings (projected) Earnings —
May 15, 2027 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Trial Milestone Phase 3
May 15, 2027 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 Trial Milestone Phase 3
June 15, 2027 A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) Trial Milestone Phase 3
July 15, 2027 A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) Trial Milestone Phase 2
September 15, 2027 Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Trial Milestone Phase 3
June 15, 2030 A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia Trial Milestone Phase 2/Phase 3

Track ALKS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ALKS in the tracker

Recent history

DateEventTypePhase
September 21, 2026 8-K filed: Reg FD disclosure, Other event Filing —
September 16, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
September 15, 2026 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder Trial Milestone Phase 3
August 12, 2026 8-K filed: Material agreement Corporate —
August 3, 2026 8-K/A filed: Leadership change Corporate —
July 28, 2026 Quarterly results filed (8-K) Earnings —
June 15, 2026 8-K filed: Reg FD disclosure, Other event Filing —
May 20, 2026 8-K filed: Leadership change Corporate —
May 12, 2026 8-K filed: Reg FD disclosure, Other event Filing —
May 5, 2026 Quarterly results filed (8-K) Earnings —
February 25, 2026 Quarterly results filed (8-K) Earnings —
February 25, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
February 12, 2026 8-K filed: Material agreement, Acquisition completed, Reg FD disclosure Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
January 6, 2026 8-K filed: Reg FD disclosure, Other event Filing —
November 19, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
November 12, 2025 8-K filed: Reg FD disclosure, Other event Filing —
November 11, 2025 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Trial Milestone Phase 2
October 28, 2025 Quarterly results filed (8-K) Earnings —
October 22, 2025 Quarterly results filed (8-K) Earnings —
September 12, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
September 12, 2025 8-K filed: Material agreement, Other event Corporate —
September 8, 2025 8-K filed: Reg FD disclosure Filing —
July 29, 2025 Quarterly results filed (8-K) Earnings —
July 21, 2025 8-K filed: Reg FD disclosure Filing —
June 19, 2025 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) Trial Milestone Phase 2
May 21, 2025 8-K filed: Leadership change Corporate —
May 1, 2025 Quarterly results filed (8-K) Earnings —
April 16, 2025 8-K filed: Other event Filing —
September 6, 2023 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.